AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which sho... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, obinutuzumab

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044444

Source: HSMN NewsFeed - October 17, 2018 Category: Pharmaceuticals Source Type: news